VEGFA and head and neck squamous cell carcinoma: Targeting VEGF/VEGFR can inhibit angiogenesis in HNSCC, which include VEGF inhibitors (bevacizumab, ramucirumab) and VEGFR inhibitors (for example, sorafenib, anlotinib, apatinib, donafenib, sunitinib, cabozatinib, and vandetanib).